Is Salivary Sialic Acid a Reliable Biomarker in the Detection of Oral Potentially Malignant Disorder and Oral Squamous Cell Carcinoma.
Biomarkers
Oral potentially malignant disorder (OPMDs)
Oral squamous cell carcinoma (OSCC)
Saliva
Total sialic acid level (TSA)
Journal
Journal of maxillofacial and oral surgery
ISSN: 0972-8279
Titre abrégé: J Maxillofac Oral Surg
Pays: India
ID NLM: 101538309
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
21
09
2019
accepted:
14
11
2019
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
16
2
2021
Statut:
ppublish
Résumé
Glycoprotein is an important constituent of saliva, and the observed increase in salivary glycoproteins such as sialic acid in oral potentially malignant disorder (OPMDs) and OSCC has stimulated the interest of researchers to explore it as a possible biomarker. The study used 60 subjects, who were divided into three groups: Group I-20 subjects who were clinically and histopathologically diagnosed with OSCC; Group II-20 subjects who were clinically and histopathologically diagnosed with OPMDs; and Group III-20 healthy subjects with good oral hygiene and with no systemic disorders detected. Two millilitres of unstimulated salivary samples was collected in a pre-sterilized container to analyse total salivary sialic acid (TSA) levels using a sialic acid kit and UV spectrophotometer. The TSA levels in OSCC (545.45 ± 100.04) were much higher when compared to the level in OPMDs (169.80 ± 66.43) and in healthy subjects (25.45 ± 16.07). Statically significant correlation was observed between different grades of OSCC. Moreover, sialic acid showed 100% sensitivity and specificity between all the three groups. Statistical analysis was done with Kruskal-Wallis, followed by Mann-Whitney post hoc test at
Identifiants
pubmed: 33584047
doi: 10.1007/s12663-019-01309-7
pii: 1309
pmc: PMC7855196
doi:
Types de publication
Journal Article
Langues
eng
Pagination
83-89Informations de copyright
© The Association of Oral and Maxillofacial Surgeons of India 2019.
Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that we have no conflict of interest.
Références
Chemphyschem. 2019 Feb 18;20(4):511-515
pubmed: 30556240
J Clin Diagn Res. 2014 Sep;8(9):ZC19-21
pubmed: 25386514
Cancer. 1991 Jan 1;67(1):135-40
pubmed: 1985709
Cancer. 2008 Jul 15;113(2):336-46
pubmed: 18521898
Int J High Risk Behav Addict. 2016 Feb 08;5(2):e27969
pubmed: 27622172
J Cancer Res Ther. 2016 Apr-Jun;12(2):634-9
pubmed: 27461623
J Oral Pathol Med. 2005 May;34(5):263-7
pubmed: 15817068
Mediators Inflamm. 2012;2012:619293
pubmed: 22577253
Eur J Dent Educ. 2008 Feb;12 Suppl 1:22-9
pubmed: 18289265
Indian J Dent Res. 2017 Jul-Aug;28(4):395-399
pubmed: 28836530
Glycoconj J. 2008 Apr;25(3):279-90
pubmed: 18158621
Indian J Clin Biochem. 2007 Sep;22(2):17-31
pubmed: 23105677
Contemp Clin Dent. 2016 Oct-Dec;7(4):451-456
pubmed: 27994410
Indian J Dent Res. 2008 Oct-Dec;19(4):288-91
pubmed: 19075429